Dyer Timothy Markinsider trades
In SEC Form 4 filings, Dyer Timothy Mark is listed as CHIEF EXECUTIVE OFFICER of Addex Therapeutics Ltd. (ADXN). Dyer Timothy Mark reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 4.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| ADXNAddex Therapeutics Ltd. | CHIEF EXECUTIVE OFFICER | 4 | Sep 4 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-04
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ADXNAddex Therapeutics Ltd. | Sep 2 | Sep 4 | D | 16,413,787 | $0.00 | $0 | 435,192 | No | Form 4 |
| ADXNAddex Therapeutics Ltd. | Sep 2 | Sep 4 | A | 16,413,787 | $0.00 | $0 | 16,848,979 | No | Form 4 |
| ADXNAddex Therapeutics Ltd. | Sep 2 | Sep 4 | D · derivative | 3,369,796 | $0.06 | $208,927 | not reported | No | Form 4 |
| ADXNAddex Therapeutics Ltd. | Sep 2 | Sep 4 | A · derivative | 3,369,796 | $0.03 | $107,833 | 3,369,796 | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.